PUBLIC LAW 110–85—SEPT. 27, 2007
121 STAT. 975
Medicine to conduct a study to assess the overall safety and quality of genetic tests and prepare a report that includes recommendations to improve Federal oversight and regulation of genetic tests. Such study shall take into consideration relevant reports by the Secretary’s Advisory Committee on Genetics, Health, and Society and other groups and shall be completed not later than 1 year after the date on which the Secretary entered into such contract. (b) RULE OF CONSTRUCTION.—Nothing in this section shall be construed as requiring Federal efforts with respect to regulatory oversight of genetic tests to cease or be limited or delayed pending completion of the report by the Secretary’s Advisory Committee on Genetics, Health, and Society or the Institute of Medicine. SEC. 1104. NIH TECHNICAL AMENDMENTS.
The Public Health Service Act (42 U.S.C. 201 et seq.) is amended— (1) in section 319C–2(j)(3)(B), by striking ‘‘section 319C– 1(h)’’ and inserting ‘‘section 319C–1(i)’’; (2) in section 402(b)(4), by inserting ‘‘minority and other’’ after ‘‘reducing’’; (3) in section 403(a)(4)(C)(iv)(III), by inserting ‘‘and postdoctoral training funded through research grants’’ before the semicolon; (4) by designating the second section 403C (relating to the drug diethylstilbestrol) as section 403D; and (5) in section 403C(a)— (A) in the matter preceding paragraph (1)— (i) by inserting ‘‘graduate students supported by the National Institutes of Health’’ after ‘‘with respect to’’; and (ii) by deleting ‘‘each degree-granting program’’; (B) in paragraph (1), by inserting ‘‘such’’ after ‘‘percentage of’’; and (C) in paragraph (2), by inserting ‘‘(not including any leaves of absence)’’ after ‘‘average time’’. SEC. 1105. SEVERABILITY CLAUSE.
42 USC 247d–3b. 42 USC 282. 42 USC 283.
42 USC 283a–3. 42 USC 283a–2.
21 USC 301 note.
If any provision of this Act, an amendment made this Act, or the application of such provision or amendment to any person or circumstance is held to be unconstitutional, the remainder of this Act, the amendments made by this Act, and the application of the provisions of such to any person or circumstances shall not be affected thereby.
Subtitle B—Antibiotic Access and Innovation SEC. 1111. IDENTIFICATION OF CLINICALLY SUSCEPTIBLE CONCENTRATIONS OF ANTIMICROBIALS.
42 USC 247d–5a.
dkrause on GSDDPC44 with PUBLAW
(a) DEFINITION.—In this section, the term ‘‘clinically susceptible concentrations’’ means specific values which characterize bacteria as clinically susceptible, intermediate, or resistant to the drug (or drugs) tested. (b) IDENTIFICATION.—The Secretary of Health and Human Services (referred to in this section as the ‘‘Secretary’’), through the Commissioner of Food and Drugs, shall identify (where such
VerDate Aug 31 2005
13:52 Jan 23, 2009
Jkt 059194
PO 00001
Frm 00973
Fmt 6580
Sfmt 6581
M:\STATUTES\2007\59194PT1.001
APPS10
PsN: 59194PT1
�
